TAGX-0003
Pre-clinical- Indications
- Alopecia Areata, Vitiligo
Company intelligence / Profile preview
TAGCyx Biotechnologies, Inc.
Meguro-ku, Tokyo, Japantagcyx.com ↗
- Ownership
- Private
- Employees
- ~18
- Development stage
- Preclinical
01
Overview
TAGCyx is a preclinical stage biotech company developing oligonucleotide aptamer-based pharmaceuticals and medical devices using their proprietary Xenoligo® technology platform.
- Therapeutic areas
- OphthalmologyNephrologyHematology
- Modalities
- Oligonucleotide aptamersDNA aptamersNucleic acid-based therapeutics
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
CAGE Bio Inc.Otsuka Chemical Co., Ltd.SBI Pharmaceuticals Co., Ltd.Resonac corporationGC Pharma corp.
Beyond the preview
Go deeper on TAGCyx Biotechnologies, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TAGCyx Biotechnologies, Inc..